Promega Seeks to Manufacture Psychedelic Psilocybin and Psilocyn
Published Date: 3/27/2025
Notice
Summary
Promega Corporation wants to become a big-time maker of special drugs called psilocybin and psilocyn, which are tightly controlled by the government. They plan to produce these substances as ingredients for medicines and are open to public comments or objections until May 27, 2025. This move affects drug makers and buyers, with no immediate cost changes announced but a clear deadline for feedback.
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
New API supplier for psilocybin and psilocyn
Promega Corporation applied on February 26, 2025 to be registered as a bulk manufacturer of psilocybin (code 7437) and psilocyn (code 7438), both Schedule I. The company plans to bulk manufacture these substances as Active Pharmaceutical Ingredients (APIs) for sale to its customers, and no other activities for these codes are authorized under this registration. Interested parties may submit comments or request a hearing on the application by May 27, 2025.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-05007, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting December 31, 2025, veterans can get buprenorphine treatment and follow-up care through telemedicine, making it easier to access help for opioid use disorder without leaving home. This change affects veterans using VA health services and aims to improve treatment access while the government reviews feedback and policies. No new costs are mentioned, but the delay gives agencies time to ensure the rules work well.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-20535, Arenbii Pharmacy LLC; Decision and Order
Arenbii Pharmacy in Texas lost its DEA license because it kept filling risky drug prescriptions without fixing obvious problems. This means they can’t legally handle certain controlled medicines anymore, protecting public safety. The decision is final, and Arenbii didn’t ask for a hearing, so the revocation starts now with no chance to appeal.
2026-20553, Decision and Order: Medpharm Research, LLC
Medpharm Research, LLC wanted to get official permission to make marijuana in bulk, but the DEA said no. The DEA found that Medpharm’s related companies were handling marijuana without permission and even selling it for recreational use, which breaks the rules. So, Medpharm’s application was denied, and they can’t legally manufacture marijuana in bulk now.
Previous / Next Documents
Previous: 2025-05282, Importer of Controlled Substances Application: Restek Corporation
Restek Corporation wants to become an official importer of certain controlled substances, including some drugs on Schedule I. People and companies already registered or applying can share their thoughts or ask for a hearing by April 28, 2025. This move could affect businesses dealing with these substances and involves a formal review process but no immediate costs are mentioned.
Next: 2025-05429, Sunshine Act Meetings
The U.S. Postal Service Board of Governors held a special meeting on March 24, 2025, that was closed to the public because urgent matters needed quick attention. This affects anyone interested in Postal Service decisions, but no new costs or timing changes were announced. The meeting focused on internal business and legal reviews, keeping things under wraps as allowed by the Sunshine Act.